TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of a Comprehensive School Health Intervention in Improving Healthy Eating and Physical Activity and Preventing Childhood Obesity
Brief Summary: The objectives were to 1) make students eat healthier and be more active; and 2) prevent overweight and obesity. Children will therefore be less likely overweight or obese. Beginning in January 2008, the Alberta Project Promoting active Living and healthy Eating in Schools (APPLE Schools) was implemented in 10 schools throughout the Canadian Province, Alberta. Full-time School Health Facilitators were placed in each of the schools to implement what is know in Canada as Comprehensive School Health (CSH). In the United States, CSH is more commonly referred to as "Coordinated School Health", while the synonymous term "Health Promoting Schools" is often used in Australia and Europe. The project was evaluated annually in the spring from 2008 to 2011 and as of 2009 evaluations included the use of time-stamped pedometers. The comparison group included approximately 150 schools that were randomly selected to reflect the population of Alberta, Canada. Twenty of these randomly selected schools also participated in data collection which involved the use of time-stamped pedometers.


Options:
A: Arm Label: A Healthy School Start Plus intervention; Type: EXPERIMENTAL; Interventions: Behavioral: A Healthy School Start Plus intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: A Healthy School Start Plus intervention | Intervention Type: BEHAVIORAL; Name: A Healthy School Start Plus intervention; Assigned to Arm(s): A Healthy School Start Plus intervention, Control
B: Arm Label: Comparison Schools; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Comprehensive School Health (CSH); Type: EXPERIMENTAL; Interventions: Other: Comprehensive School Health (CSH) | Intervention Type: OTHER; Name: Comprehensive School Health (CSH); Assigned to Arm(s): Comprehensive School Health (CSH)
C: Arm Label: PAAC-R; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Across the Curriculum | Arm Label: PAAC-T; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Across the Curriculum | Intervention Type: BEHAVIORAL; Name: Physical Activity Across the Curriculum; Assigned to Arm(s): PAAC-R, PAAC-T
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Experimental | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Experimental; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Community-Academic Partnership to Address Disparities in Obesity Among Youth
Brief Summary: Objectives: We conducted a randomized controlled trial (RCT) of Students for Nutrition and eXercise (SNaX), a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing.

Methods: We randomly selected schools from the Los Angeles Unified School District (LAUSD) and assigned five to the intervention group and five to a wait-list control group. School records were obtained for number of fruits and vegetables served, students served lunch, and snacks sold per attending student. Pre- and post-intervention surveys assessed psychosocial variables among 2,997 seventh-graders (75% of all seventh-graders across schools).

Hypotheses: For the RCT of SNaX, we hypothesized that SNaX would lead to increases in the proportion of students served in the cafeteria (because SNaX markets cafeterias' healthy foods); increased fruit and vegetable servings (because SNaX increases access to sliced/bite-sized fruits and vegetables); decreased school store snack sales; and greater water consumption. We also hypothesized that SNaX would lead to more positive attitudes about the cafeteria and water, improve obesity-prevention knowledge, and increase intentions to drink water.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Students for Nutrition and eXercise; Type: EXPERIMENTAL; Interventions: Behavioral: Students for Nutrition and eXercise | Intervention Type: BEHAVIORAL; Name: Students for Nutrition and eXercise; Assigned to Arm(s): Students for Nutrition and eXercise
B: Arm Label: Mentoring to be Active; Type: EXPERIMENTAL; Interventions: Behavioral: Mentoring to be Active with Accelerometers | Arm Label: Planning to be Active; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Planning to be Active with Accelerometers | Arm Label: Peer Mentors; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High School Teachers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mentoring to be Active with Accelerometers; Assigned to Arm(s): Mentoring to be Active | Intervention Type: BEHAVIORAL; Name: Planning to be Active with Accelerometers; Assigned to Arm(s): Planning to be Active
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity intervention | Intervention Type: BEHAVIORAL; Name: Physical activity intervention; Assigned to Arm(s): Physical activity intervention
D: Intervention Type: BEHAVIORAL; Name: FLOW; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: SelfHelp; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)
Brief Summary: The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.


Options:
A: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg
C: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm Mepolizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab 100mg | Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Mepolizumab 100mg, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Mepolizumab 100mg; Assigned to Arm(s): Arm Mepolizumab 100 mg, Arm Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)
Brief Summary: The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.


Options:
A: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determining Optimal Post-Stroke Exercise (DOSE)
Brief Summary: The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.


Options:
A: Arm Label: enhanced upper-extremity program, EUEP; Type: EXPERIMENTAL; Interventions: Other: UFT | Arm Label: enhanced lower-extremity program,ELLP); Type: EXPERIMENTAL; Interventions: Other: LFT | Intervention Type: OTHER; Name: UFT; Assigned to Arm(s): enhanced upper-extremity program, EUEP | Intervention Type: OTHER; Name: LFT; Assigned to Arm(s): enhanced lower-extremity program,ELLP)
B: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization
C: Arm Label: Stroke Management Program (SMP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stroke Management Program (SMP) | Arm Label: Stroke Monitoring Program (SMonP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Monitoring Program (SMonP) | Arm Label: Stroke Supplementary Program (SSP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Supplementary Program (SSP) | Intervention Type: BEHAVIORAL; Name: Stroke Management Program (SMP); Assigned to Arm(s): Stroke Management Program (SMP) | Intervention Type: BEHAVIORAL; Name: Stroke Monitoring Program (SMonP); Assigned to Arm(s): Stroke Monitoring Program (SMonP) | Intervention Type: BEHAVIORAL; Name: Stroke Supplementary Program (SSP); Assigned to Arm(s): Stroke Supplementary Program (SSP)
D: Arm Label: Variable high-intensity Training; Type: EXPERIMENTAL; Interventions: Behavioral: exercise | Arm Label: Variable low-intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Arm Label: Constant High Intensity Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): Constant High Intensity Training, Variable high-intensity Training, Variable low-intensity training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determining Optimal Post-Stroke Exercise (DOSE)
Brief Summary: The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.


Options:
A: Arm Label: real tDCS + TOCT; Type: EXPERIMENTAL; Interventions: Device: real tDCS + TOCT | Arm Label: sham tDCS + TOCT; Type: ACTIVE_COMPARATOR; Interventions: Device: sham tDCS + TOCT | Intervention Type: DEVICE; Name: sham tDCS + TOCT; Assigned to Arm(s): sham tDCS + TOCT | Intervention Type: DEVICE; Name: real tDCS + TOCT; Assigned to Arm(s): real tDCS + TOCT
B: Arm Label: Stroke Management Program (SMP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stroke Management Program (SMP) | Arm Label: Stroke Monitoring Program (SMonP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Monitoring Program (SMonP) | Arm Label: Stroke Supplementary Program (SSP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Supplementary Program (SSP) | Intervention Type: BEHAVIORAL; Name: Stroke Management Program (SMP); Assigned to Arm(s): Stroke Management Program (SMP) | Intervention Type: BEHAVIORAL; Name: Stroke Monitoring Program (SMonP); Assigned to Arm(s): Stroke Monitoring Program (SMonP) | Intervention Type: BEHAVIORAL; Name: Stroke Supplementary Program (SSP); Assigned to Arm(s): Stroke Supplementary Program (SSP)
C: Arm Label: Fit For Function Program; Type: EXPERIMENTAL; Interventions: Other: Fit For Function Program | Arm Label: Standard YMCA membership; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard YMCA membership | Intervention Type: OTHER; Name: Fit For Function Program; Assigned to Arm(s): Fit For Function Program | Intervention Type: OTHER; Name: Standard YMCA membership; Assigned to Arm(s): Standard YMCA membership
D: Arm Label: Rehabilitation training; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): Rehabilitation training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determining Optimal Post-Stroke Exercise (DOSE)
Brief Summary: The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.


Options:
A: Arm Label: Stroke Management Program (SMP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stroke Management Program (SMP) | Arm Label: Stroke Monitoring Program (SMonP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Monitoring Program (SMonP) | Arm Label: Stroke Supplementary Program (SSP); Type: EXPERIMENTAL; Interventions: Behavioral: Stroke Supplementary Program (SSP) | Intervention Type: BEHAVIORAL; Name: Stroke Management Program (SMP); Assigned to Arm(s): Stroke Management Program (SMP) | Intervention Type: BEHAVIORAL; Name: Stroke Monitoring Program (SMonP); Assigned to Arm(s): Stroke Monitoring Program (SMonP) | Intervention Type: BEHAVIORAL; Name: Stroke Supplementary Program (SSP); Assigned to Arm(s): Stroke Supplementary Program (SSP)
B: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
D: Arm Label: group 1: standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Procedure: standard physiotherapy | Arm Label: group 2: experimental physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: experimental physiotherapy | Intervention Type: PROCEDURE; Name: standard physiotherapy; Assigned to Arm(s): group 1: standard physiotherapy | Intervention Type: PROCEDURE; Name: experimental physiotherapy; Assigned to Arm(s): group 2: experimental physiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complex Mental and Social Activities to Promote Cognitive Function in Older Adults With Chronic Stroke: A Randomized Controlled Trial
Brief Summary: The investigators will conduct a randomized controlled trial study to provide preliminary evidence of efficacy of exercise training or a complex mental and social activities program for improving cognitive function in older adults with chronic stroke, compared with a stretch and relaxation program.


Options:
A: Arm Label: OT arm; Type: N/A; Interventions: N/A
B: Arm Label: Self-Management group-intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management group-intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Intervention Type: BEHAVIORAL; Name: Self-Management group-intervention; Assigned to Arm(s): Self-Management group-intervention | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Complex mental and social activities; Type: EXPERIMENTAL; Interventions: Behavioral: Complex mental and social activities | Arm Label: Control: stretching and relaxation program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control: stretching and relaxation program | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Complex mental and social activities; Assigned to Arm(s): Complex mental and social activities | Intervention Type: BEHAVIORAL; Name: Control: stretching and relaxation program; Assigned to Arm(s): Control: stretching and relaxation program
D: Arm Label: Mentor; Type: EXPERIMENTAL; Interventions: Behavioral: Mentor | Arm Label: Traditional rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mentor | Intervention Type: BEHAVIORAL; Name: Mentor; Assigned to Arm(s): Mentor, Traditional rehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.
Brief Summary: The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.


Options:
A: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group
B: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)
C: Arm Label: orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: orthokeratology lenses | Arm Label: single-vision spectacle lenses; Type: OTHER; Interventions: Device: single-vision spectacle lenses | Intervention Type: DEVICE; Name: orthokeratology lenses; Assigned to Arm(s): orthokeratology lenses | Intervention Type: DEVICE; Name: single-vision spectacle lenses; Assigned to Arm(s): single-vision spectacle lenses
D: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.
Brief Summary: The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.


Options:
A: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: Test Lens A; Type: EXPERIMENTAL; Interventions: Device: Soft Contact Test Lens A | Arm Label: Test Lens C; Type: EXPERIMENTAL; Interventions: Device: Soft Contact Test Lens C | Intervention Type: DEVICE; Name: Soft Contact Test Lens A; Assigned to Arm(s): Test Lens A | Intervention Type: DEVICE; Name: Soft Contact Test Lens C; Assigned to Arm(s): Test Lens C
D: Arm Label: Single-vision glasses; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Orthokeratology with normal compression factor; Type: SHAM_COMPARATOR; Interventions: Device: Orthokeratology | Arm Label: Orthokeratology with increased compression factor; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthokeratology | Intervention Type: DEVICE; Name: Orthokeratology; Assigned to Arm(s): Orthokeratology with increased compression factor, Orthokeratology with normal compression factor

Answer: A